Elad Jacoby

5.2k total citations
76 papers, 2.2k citations indexed

About

Elad Jacoby is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Elad Jacoby has authored 76 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 20 papers in Molecular Biology and 15 papers in Immunology. Recurrent topics in Elad Jacoby's work include CAR-T cell therapy research (55 papers), Virus-based gene therapy research (12 papers) and Immune Cell Function and Interaction (12 papers). Elad Jacoby is often cited by papers focused on CAR-T cell therapy research (55 papers), Virus-based gene therapy research (12 papers) and Immune Cell Function and Interaction (12 papers). Elad Jacoby collaborates with scholars based in Israel, United States and Germany. Elad Jacoby's co-authors include Michal J. Besser, Terry J. Fry, Yinmeng Yang, Jacob Schachter, Amos Toren, Amilia Meir, Christopher D. Chien, Abraham Avigdor, Arnon Nagler and Haiying Qin and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Elad Jacoby

68 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elad Jacoby Israel	22	1.5k	818	528	505	335	76	2.2k
Keichiro Mihara Japan	21	1.2k 0.8×	914 1.1×	645 1.2×	340 0.7×	278 0.8×	70	2.4k
Fabiana Perna United States	20	1.5k 1.0×	1.3k 1.6×	643 1.2×	455 0.9×	399 1.2×	62	2.7k
Olga Dakhova United States	24	2.4k 1.6×	1.1k 1.3×	914 1.7×	822 1.6×	712 2.1×	40	3.1k
Meng-Fen Wu United States	16	2.4k 1.6×	815 1.0×	1.0k 1.9×	743 1.5×	627 1.9×	18	2.9k
Gerrit Weber United States	19	993 0.7×	437 0.5×	677 1.3×	285 0.6×	314 0.9×	28	1.5k
Steven L. Highfill United States	23	1.6k 1.1×	719 0.9×	1.7k 3.3×	348 0.7×	321 1.0×	86	2.9k
Zeguo Zhao United States	13	1.6k 1.0×	666 0.8×	881 1.7×	478 0.9×	546 1.6×	21	2.1k
Rayne H. Rouce United States	17	1.6k 1.0×	554 0.7×	924 1.8×	488 1.0×	209 0.6×	54	2.0k
Biagio De Angelis Italy	22	1.2k 0.8×	543 0.7×	774 1.5×	352 0.7×	326 1.0×	44	1.7k

Countries citing papers authored by Elad Jacoby

Since Specialization

Citations

This map shows the geographic impact of Elad Jacoby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elad Jacoby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elad Jacoby more than expected).

Fields of papers citing papers by Elad Jacoby

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elad Jacoby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elad Jacoby. The network helps show where Elad Jacoby may publish in the future.

Co-authorship network of co-authors of Elad Jacoby

This figure shows the co-authorship network connecting the top 25 collaborators of Elad Jacoby. A scholar is included among the top collaborators of Elad Jacoby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elad Jacoby. Elad Jacoby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lamble, Adam J., Sandra D. Bohling, Kara L. Davis, et al.. (2025). Harmonization on defining B‐cell recovery post CD19‐CAR T‐cell therapy in B‐cell acute lymphoblastic leukemia: An international consensus statement. HemaSphere. 9(11). e70247–e70247.

Shouval, Roni, Shalev Fried, Ivetta Danylesko, et al.. (2025). Pretreatment pulmonary function testing has limited utility in B-cell lymphoma treated with CD19 CAR T cells. Blood Advances. 9(7). 1720–1725. 1 indexed citations

Danylesko, Ivetta, Noga Shem‐Tov, Ronit Yerushalmi, et al.. (2024). Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression. Current Research in Translational Medicine. 72(4). 103471–103471. 5 indexed citations

Marcu‐Malina, Victoria, Ifat Sarouk, Amilia Meir, et al.. (2024). Genotoxicity Associated with Retroviral CAR Transduction of ATM -Deficient T Cells. Blood Cancer Discovery. 5(4). 267–275. 1 indexed citations

Fried, Shalev, Ivetta Danylesko, Orit Itzhaki, et al.. (2023). High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia. Blood. 142(Supplement 1). 6875–6875.

Fried, Shalev, Orit Itzhaki, Ronit Yerushalmi, et al.. (2023). Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma. Leukemia & lymphoma. 64(12). 1956–1963. 3 indexed citations

Yates, Bonnie, Seth M. Steinberg, Constance M. Yuan, et al.. (2023). Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure. Transplantation and Cellular Therapy. 29(9). 574.e1–574.e10. 4 indexed citations

Danylesko, Ivetta, Noga Shem‐Tov, Ronit Yerushalmi, et al.. (2023). P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION. HemaSphere. 7(S3). e4369964–e4369964. 1 indexed citations

Fried, Shalev, Roni Shouval, Nira Varda‐Bloom, et al.. (2022). Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel. Leukemia & lymphoma. 63(14). 3385–3393. 5 indexed citations

10.

Brivio, Erica, Harm van Tinteren, Susan R. Rheingold, et al.. (2022). Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia. Leukemia. 37(1). 53–60. 13 indexed citations

11.

Kedmi, Meirav, Roni Shouval, Shalev Fried, et al.. (2022). Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma. Transplantation and Cellular Therapy. 28(5). 251–257. 24 indexed citations

12.

Brivio, Erica, Susan R. Rheingold, Allison Barz Leahy, et al.. (2021). Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia. Blood. 138(Supplement 1). 3824–3824. 2 indexed citations

13.

Albert, Michael H., Manfred Hoenig, Fabian Hauck, et al.. (2021). Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders. Bone Marrow Transplantation. 56(9). 2248–2258. 5 indexed citations

14.

Itzhaki, Orit, Elad Jacoby, Arnon Nagler, et al.. (2020). Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients. Journal for ImmunoTherapy of Cancer. 8(1). e000148–e000148. 37 indexed citations

15.

Danylesko, Ivetta, Roni Shouval, Noga Shem‐Tov, et al.. (2020). Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. Bone Marrow Transplantation. 56(5). 1134–1143. 23 indexed citations

16.

Jacoby, Elad, Noah Gruber, Nira Varda‐Bloom, et al.. (2020). Promising Results for Kearns-Sayre Syndrome of First in Man Treatment by Mitochondrial Augmentation Therapy (457). Neurology. 94(15_supplement). 6 indexed citations

17.

Beider, Katia, Michal J. Besser, Jacob Schachter, et al.. (2019). Upregulation of Senescent/Exhausted Phenotype of CAR T Cells and Induction of Both Treg and Myeloid Suppressive Cells Correlate with Reduced Response to CAR T Cell Therapy in Relapsed/Refractory B Cell Malignancies. Blood. 134(Supplement_1). 3234–3234. 12 indexed citations

18.

Ungar, Lior, Anton Wohl, Elad Jacoby, et al.. (2019). Role of Klotho Protein in Tumor Genesis, Cancer Progression, and Prognosis in Patients with High-Grade Glioma. World Neurosurgery. 130. e324–e332. 17 indexed citations

19.

Jacoby, Elad, Yair Anikster, Nira Varda‐Bloom, et al.. (2018). First-in-Human Mitochondrial Augmentation of Hematopoietic Stem Cells in Pearson Syndrome. Blood. 132(Supplement 1). 1024–1024. 10 indexed citations

20.

Yang, Yinmeng, Elad Jacoby, & Terry J. Fry. (2015). Challenges and opportunities of allogeneic donor-derived CAR T cells. Current Opinion in Hematology. 22(6). 509–515. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact